


CLAIMS

1. A compound represented by structural formula IV:



or a pharmaceutically acceptable salt thereof, wherein:


R^2 is selected from optionally substituted heteroaryl having 5 to 15 ring atoms and optionally substituted aryl having 6 to 12 ring atoms,


wherein the optional substituents on R^2 groups are 1, 2 or 3 substituents independently selected from halogen, C_1 - C_4 alkyl, halo- C_1 - C_4 alkyl, C_1 - C_4 alkoxy, C_1 - C_4 thioalkoxy, hydroxyl, amino, C_1 - C_4 alkylamino, C_1 - C_4 dialkylamino, sulfhydryl, cyano, C_6 aryl and heteroaryl having 5 or 6 ring atoms.


2. The compound of claim 1, wherein R^2 is an optionally substituted heteroaryl having 5 to 15 ring atoms.
3. The compound of claim 2, wherein R^2 is an optionally substituted 5-6-membered heteroaryl having 1, 2 or 3 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur.
4. The compound of claim 3, wherein R^2 is an optionally substituted 5-membered heteroaryl having 1, 2 or 3 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur.
5. The compound of claim 4, wherein R^2 is an optionally substituted pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, or oxadiazolyl.
6. The compound of claim 3, wherein R^2 is an optionally substituted 6-membered heteroaryl having 1, 2 or 3 heteroatoms independently selected from the group

consisting of nitrogen, oxygen and sulfur.

7. The compound of claim 6, wherein R² is an optionally substituted pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl or triazinyl.
8. The compound of any one of claims 1-7, wherein R² is optionally substituted with 1, 2 or 3 substituents independently selected from fluoro, chloro, C₁-C₄ alkyl, -CF₃, amino and cyano.
9. A compound of Claim 1, represented by any one of the following structural formulas:









or a pharmaceutically acceptable salt of any of the foregoing.


10. The compound of claim 9, selected from:






or a pharmaceutically acceptable salt of any of the foregoing, wherein the exocyclic double bond is in a trans configuration.


11. The compound of claim 9, selected from:





or a pharmaceutically acceptable salt of any of the foregoing, wherein the exocyclic double bond is in a cis configuration.

12. A pharmaceutically acceptable composition comprising a compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
13. A compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof, or a composition of claim 12, for use in:
 - (a) the treatment of a disorder associated with CRM1 activity; or
 - (b) promoting wound healing in a subject in need thereof.
14. The compound for use according to claim 13, wherein the disorder is selected from a proliferative disorder, cancer, an inflammatory disorder, an autoimmune disorder, a viral infection, an ophthalmological disorder, a neurodegenerative disorder, a disorder of abnormal tissue growth, a disorder related to food intake, an allergy, and a respiratory disorder.
15. The compound for use according to claim 13, wherein the disorder is cancer.
16. The compound of claim 1 represented by the following structural formula



or a pharmaceutically acceptable salt thereof.

17. The compound for use according to claim 13, wherein the disorder is multiple myeloma.